Overview

A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke

Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
0
Participant gender:
All
Summary
A study to Evaluate the Efficacy and Safety of Renexin CR in patients with Acute Non-cardioembolic Ischemic Stroke
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
SK Chemicals Co., Ltd.
Treatments:
Clopidogrel
Criteria
Inclusion Criteria:

1) Patients identified as acute non-cardioembolic ischemic stroke on MRI within 72 hours of
onset of symptoms of cerebral infarction.

Exclusion Criteria:

1. Patients with active cancer; vascular malformation, abscess, or other major
non-ischemic brain disease (e.g., multiple sclerosis).

2. With a modified Rankin Score (mRS) of 3 or higher before onset.

3. Underwent intravenous thrombolytic therapy (intravenous rtPA) or mechanical
thrombectomy within 24 hours of the screening visit.

4. History of hypersensitivity to IP or components

5. Not suitable for aspirin administration at the discretion of the investigator